Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US.
Glenmark Pharmaceuticals’ specialty assets, including its proposed biosimilar to Xolair (omalizumab), will continue to be housed inside Glenmark and will not form part of a spun-out ‘innovation’ business that the Indian firm has announced plans to establish in the US.
As would be expected, Glenmark’s generic assets will also remain with the residual Glenmark business, the company confirmed. The transfer...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
